OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Opinion on Drug Discovery is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Lessons learned from phenotypic drug discovery efforts	176
Advances in the discovery of drugs that treat pulmonary arterial hypertension	148
Advances in ion channel high throughput screening: where are we in 2023?	112
Reality check: lipid-oligonucleotide conjugates for therapeutic applications	93
γ-Secretase: once and future drug target for Alzheimer’s disease	68
Discovery of novel cathepsin K inhibitors for osteoporosis treatment using a deep learning-based strategy	66
Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery	45
What is the plausibility that all drugs will be designed by computers by the end of the decade?	43
Scaffold hopping approaches for dual-target antitumor drug discovery: opportunities and challenges	42
Methods in marine natural product drug discovery: what’s new?	41
Strategies for targeting RNA with small molecule drugs	41
A comprehensive update on the use of molecular topology applications for anti-infective drug discovery	40
Bisquinoline as a promising scaffold in anti-infective drug discovery: the current state of the art and future prospects	38
Tools and techniques for the discovery of therapeutic aptamers: recent advances	38
Designing drugs against leishmaniasis: is targeting the sterol biosynthesis pathway the answer?	35
Understanding the impact of binding free energy and kinetics calculations in modern drug discovery	35
The preclinical discovery and development of gepirone hydrochloride extended-release tablets: the first oral selective 5-HT1A receptor agonist for the treatment of major depressive disorder	35
The potential of microfluidic platforms for neuron differentiation and pain modeling in novel drug discovery	34
Phenotypic screening for new heart failure therapeutics: scalable animal modeling in zebrafish	33
The rules often neglected in current medicinal chemistry	32
A cautionary tale of paradox and false positives in cannabidiol research	32
Novel insights into structure–activity relationships of kynurenine 3-monooxygenase inhibitors (KMOis) with emphasis on chemical space, activity landscape exploration	32
C. elegans : a prominent platform for modeling and drug screening in neurological disorders	30
An update on knowledge graphs and their current and potential applications in drug discovery	29
Acoustic ejection mass spectrometry: fundamentals and applications in high-throughput drug discovery	29

Virtual screening: hope, hype, and the fine line in between	29
Molecular hybridization: a powerful tool for multitarget drug discovery	28
Water in drug design: pitfalls and good practices	28
Calcium channel blockers’ contribution to overcoming Current drug discovery challenges in Alzheimer’s disease	28